NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$2.28 USD
-0.02 (-0.87%)
Updated Jun 20, 2024 04:00 PM ET
After-Market: $2.31 +0.03 (1.32%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
NovaBay Pharmaceuticals, Inc. [NBY]
Reports for Purchase
Showing records 61 - 80 ( 109 total )
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We launch coverage of NovaBay Pharmaceuticals with a Buy rating and a $5.50/share price target
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q17 Financial Results; 2017 $19M Revenue Guidance Reiterated; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q17 Financial Results; 2017 $19M Revenue Guidance Reiterated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
2016 Revenue up 172%; 60% Growth Expected in 2017; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
2016 Revenue up 172%; 60% Growth Expected in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are initiating coverage of NovaBay Pharmaceuticals, Inc. with a Buy rating and 12-month target of $6.00 per share
Provider: H.C. Wainwright & Co., Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and 12-month target of $6.00 per share.
Provider: Rodman & Renshaw, Co.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Nonresistant antibiotic in multiple late-stage trials
Provider: REDCHIP
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.